18 completed, 4 recruiting, 3 terminated, 2 active not recruiting. 17 Phase 2, 6 Phase 3, 4 Phase 4, 2 Not applicable.
Follow Alopecia universalis: new trials by email Literature Review of Alopecia universalis trials Research Report on Alopecia universalis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA) Tofacitinib, Methotrexate - Alopecia Areata, Alopecia Totalis (AT) | Phase 4 | Not yet recruiting | Hayat Abad Medical Complex, Peshawar | 78 | 2026-02-15 | 2026-02-12 |
| Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study Methotrexate, Cyclosporin (CSA) - Alopecia Areata(AA), Alopecia Areata (AA) | Phase 4 | Recruiting | Erasmus Medical Center | 50 | 2025-11-01 | 2026-02-02 |
| Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata Vancomycin, Neomycin and MTT capsules, Placebo capsules - Alopecia Areata, Alopecia Totalis | Phase 2 | Recruiting | University of Minnesota | 40 | 2025-08-21 | 2026-06-26 |
| A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg - Alopecia Areata | Phase 3 | Recruiting | Pfizer | 674 | 2025-04-01 | 2026-10-20 |
| Systemic Treatments for Alopecia Areata Registry Alopecia Areata, Alopecia Totalis | Recruiting | Erasmus Medical Center | 10000 | 2024-01-17 | 2024-02-28 | |
| Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi. Tofacitinib - Alopecia Areata, Alopecia Totalis | Phase 3 | Completed | Jinnah Hospital | 30 | 2023-07-01 | 2024-02-26 |
| Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata EQ101 - Alopecia Areata, Alopecia | Phase 2 | Completed | Equillium | 36 | 2022-12-19 | 2025-04-10 |
| Clinical Application of Stem Cell Educator Therapy in Alopecia Areata Stem Cell Educator therapy - Alopecia Areata, Alopecia Totalis | Phase 2 | Active not recruiting | Throne Biotechnologies Inc. | 20 | 2022-09-20 | 2026-09-30 |
| The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic Exposure of interest - Alopecia Areata, Alopecia Totalis | Completed | Faculty Hospital Kralovske Vinohrady | 123 | 2021-10-15 | 2024-12-03 | |
| Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata BNZ-1, Normal saline - Alopecia Areata, Alopecia Totalis | Phase 2 | Withdrawn | Equillium | 2021-10-01 | 2022-09-16 | |
| PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA PF-06651600, Placebo - Alopecia Areata | Phase 2 | Terminated | Pfizer | 71 | 2020-09-15 | 2025-07-11 |
| Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation Tofacitinib - Alopecia Totalis/Universalis, Alopecia Areata(AA) | Completed | NanoAlvand | 296 | 2020-08-04 | 2025-08-07 | |
| Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata Fecal material transfer therapy, 4mm Punch Biopsy of Scalp, Blood draw - Alopecia Areata, Alopecia Totalis | Phase 2 | Withdrawn | Lindsey Bordone | 2019-12-19 | 2022-03-21 | |
| Long-Term PF-06651600 for the Treatment of Alopecia Areata PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine - Alopecia Areata | Phase 3 | Completed | Pfizer | 1057 | 2019-07-18 | 2026-04-09 |
| ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT) ATI 502 0.46% Topical Solution - Alopecia Areata, Alopecia Universalis | Phase 2 | Terminated | Aclaris Therapeutics, Inc. | 56 | 2019-01-15 | 2020-10-06 |
| Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Tofacitinib - Alopecia Areata | Phase 4 | Completed | Institute of Dermatology, Thailand | 19 | 2019-01-12 | 2022-03-31 |
| PF-06651600 for the Treatment of Alopecia Areata PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2 - Alopecia Areata | Phase 2 / Phase 3 | Completed | Pfizer | 718 | 2018-12-03 | 2022-02-24 |
| A Randomised Control Trial of Integrative Cognitive Behavioural Therapy for Alopecia Integrative Cognitive Behavioural Therapy - Alopecia | Not applicable | Completed | City, University of London | 15 | 2018-12-01 | 2020-09-22 |
| Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata ATI-50002 - Alopecia Areata, Alopecia Totalis | Phase 2 | Completed | Aclaris Therapeutics, Inc. | 1 | 2018-04-11 | 2019-12-11 |
| Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD) Dupilumab, Placebo - Alopecia Areata | Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 60 | 2018-01-09 | 2022-09-13 |
Showing 20 of 31. Sign in to see all of them.
Alopecia Areata (29) · Alopecia (14) · Autoimmune Diseases (3) · Hair Diseases (3) · Anemia, Pernicious (1) · Arthritis, Rheumatoid (1) · COVID-19 (1) · Colitis, Ulcerative (1) · Crohn Disease (1) · Dermatitis, Atopic (1) · Diabetes Mellitus, Type 1 (1) · Diffuse alopecia (1) · Down Syndrome (1) · Graves Disease (1)
Hypotrichosis (29) · Skin Diseases (29) · Skin and Connective Tissue Diseases (29) · Hair Diseases (26) · Alopecia (15) · Pathological Conditions, Anatomical (14) · Pathological Conditions, Signs and Symptoms (14) · Immune System Diseases (3) · Abnormalities, Multiple (1) · Anemia (1) · Anemia, Macrocytic (1) · Anemia, Megaloblastic (1) · Ankylosis (1) · Arthritis (1) · Autoimmune Diseases of the Nervous System (1)
tofacitinib (5) · PF-06651600 (3) · Methotrexate (2) · Saline Solution (2) · Bexarotene (1) · Blood Specimen Collection (1) · Botulinum Toxins, Type A (1) · Cyclosporine (1) · Methylprednisolone Hemisuccinate (1) · Neomycin (1) · Solutions (1) · Tetanus Toxoid (1) · Vaccines (1) · Vancomycin (1) · dupilumab (1)
Pfizer (5) · Aclaris Therapeutics, Inc. (3) · Equillium (2) · Erasmus Medical Center (2) · M.D. Anderson Cancer Center (2) · Yale University (2) · City, University of London (1) · Emma Guttman (1) · Faculty Hospital Kralovske Vinohrady (1) · Hayat Abad Medical Complex, Peshawar (1) · Icahn School of Medicine at Mount Sinai (1) · Incyte Corporation (1) · Institute of Dermatology, Thailand (1) · Jinnah Hospital (1) · King Saud University (1)
United States (17) · Australia (4) · Canada (4) · Czechia (4) · Poland (4) · United Kingdom (4) · China (3) · Japan (3) · South Korea (3) · Spain (3) · Taiwan (3) · Argentina (2) · Chile (2) · Colombia (2) · Germany (2)
Madeleine Duvic, MD (2) · Anthony E Oro, M.D., Ph.D. (1) · Brett King, MD (1) · Brett King, MD, PhD (1) · Chinmanat Lekhavat, MD (1) · Emma Guttman, MD, PhD (1) · Emma Guttman, MD,PhD (1) · Ghada A Binsaif, MD (1) · Kathleen Butler, MD (1) · Lindsey Bordone, MD (1) · Maria K Hordinsky, MD (1) · Rasthawathana Desomchoke, MD (1) · Rattapon Thoungtong, MD (1) · Sharon Hart, Doctorate (1)
PMID 38263353, PMID 41917311, PMID 42481842, PMID 27699252, PMID 28300084, PMID 28619556, PMID 29273099, PMID 39962358, PMID 42823604, PMID 14582678, PMID 16417220, PMID 17236136, PMID 17637820, PMID 18329131, PMID 18489053, PMID 20115945, PMID 22233865, PMID 22512484, PMID 22524397, PMID 22833322, PMID 24202232, PMID 24940651, PMID 25896390, PMID 26183987, PMID 27816293, PMID 28139263, PMID 29273100, PMID 29273101, PMID 29466675, PMID 29723356, PMID 29791718, PMID 30073292, PMID 31799258, PMID 33376289, PMID 34211288, PMID 34460948, PMID 36177791, PMID 37062298, PMID 37339501, PMID 37403610, PMID 37521227, PMID 37707764, PMID 37917289, PMID 37955531, PMID 38823686, PMID 39254890, PMID 39328096, PMID 39423930, PMID 39432738, PMID 39441519
2018 (1), 2023 (1)